Skip to main content

Advertisement

SpringerLink
Log in

Age-related effects and gender differences in Japanese healthy controls for [123I] FP-CIT SPECT

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

Dopamine transporter (DAT) imaging with [123I]FP-CIT (DaTSCAN) is a widely used diagnostic tool for Parkinsonism and dementia. Since it was approved by the Japanese Ministry of Health, Labor, and Welfare in 2013, there have been no articles focusing on a Japanese normal population. The aim of this study was to examine the effect of aging and gender on DAT availability in Japanese people.

Methods

SPECT imaging of 30 healthy Japanese controls (17 males, 13 females; range 50–86 years, mean 70 years) was performed. SPECT images were reconstructed using a three-dimensional order subset expectation maximization (OSEM) algorithm with correction of the point spread function and scatter correction, without attenuation correction. The specific binding ratio (SBR) was calculated by DATview software. Statistical analyses were performed using linear regression analysis, analysis of variance, and multiple comparison analysis.

Results

A strong correlation between the SBR and age was observed. The correlation coefficient in males and females were −0.566 and −0.502, respectively. The analysis of variance revealed that aging led to a decline of the SBR, and a significant difference (p = 0.005) was observed among generations. Gender also affected the SBR, and there was a significant difference between males and females (p = 0.036). The SBR in females was higher than in males. Consequently, the multiple comparison revealed a significant difference between 50s and 70s (p = 0.015) and 50s and 80s (p = 0.006).

Conclusions

This is the first [123I]FP-CIT SPECT study on subjects with normal dopamine function in Asian countries. This study provides a database of [123I]FP-CIT SPECT in Japanese healthy controls. Higher DAT availability was found in women than in men. An average age-related decline in DAT availability of 8.9% was found in both genders. The data collected in this study would be helpful for Japanese physicians to make a differential diagnosis in Parkinsonian syndrome.

The registration identification number for this study is UMIN000018045.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. European Medicines Agency. Prescribing information for DaTSCAN Website. 2017. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000266/human_med_000739.jsp&mid=WC0b01ac058001d124. Accessed 13 Mar 2017.

  2. FDA. Prescribing information for DaTscan Website. 2017. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022454sOrig1s000Lbl.pdf. Accessed 13 Mar 2017.

  3. Lavalaye J, Booij J, Reneman L, Habraken JB, van Royen EA. Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med. 2000;27(7):867–9.

    Article  CAS  PubMed  Google Scholar 

  4. van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM, et al. Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry. 2002;10(1):36–43.

    Article  PubMed  Google Scholar 

  5. Best SE, Sarrel PM, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM, et al. Striatal dopamine transporter availability with [123I]beta-CIT SPECT is unrelated to gender or menstrual cycle. Psychopharmacology (Berl). 2005;183(2):181–9.

    Article  CAS  Google Scholar 

  6. van Dyck CH, Malison RT, Jacobsen LK, Seibyl JP, Staley JK, Laruelle M, et al. Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med. 2005;46(5):745–51.

    PubMed  Google Scholar 

  7. Eusebio A, Azulay JP, Ceccaldi M, Girard N, Mundler O, Guedj E. Voxel-based analysis of whole-brain effects of age and gender on dopamine transporter SPECT imaging in healthy subjects. Eur J Nucl Med Mol Imaging. 2012;39(11):1778–83.

    Article  CAS  PubMed  Google Scholar 

  8. Jakobson Mo S, Larsson A, Linder J, Birgander R, Edenbrandt L, Stenlund H, et al. (1)(2)(3)I-FP-Cit and 123I-IBZM SPECT uptake in a prospective normal material analysed with two different semiquantitative image evaluation tools. Nucl Med Commun. 2013;34(10):978–89.

    Article  PubMed  Google Scholar 

  9. Nobili F, Naseri M, De Carli F, Asenbaum S, Booij J, Darcourt J, et al. Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database. Eur J Nucl Med Mol Imaging. 2013;40(4):565–73.

    Article  PubMed  Google Scholar 

  10. Thomsen G, Knudsen GM, Jensen PS, Ziebell M, Holst KK, Asenbaum S, et al. No difference in striatal dopamine transporter availability between active smokers, ex-smokers and non-smokers using [123I]FP-CIT (DaTSCAN) and SPECT. EJNMMI Res. 2013;3(1):39.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Varrone A, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Booij J, et al. European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging. 2013;40(2):213–27.

    Article  CAS  PubMed  Google Scholar 

  12. van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Wallace E, Zoghbi SS, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CITSPECT. J Nucl Med. 1995;36(7):1175–81.

    PubMed  Google Scholar 

  13. Matsutomo N, Nagaki A, Yamao F, Sasaki M. Optimization of iterative reconstruction parameters with 3-dimensional resolution recovery, scatter and attenuation correction in (1)(2)(3)I-FP-CIT SPECT. Ann Nucl Med. 2015;29(7):636–42.

    Article  CAS  PubMed  Google Scholar 

  14. Tossici-Bolt L, Hoffmann SM, Kemp PM, Mehta RL, Fleming JS. Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging. 2006;33(12):1491–9.

    Article  PubMed  Google Scholar 

  15. Ujike H, Harano M, Inada T, Yamada M, Komiyama T, Sekine Y, et al. Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. Pharmacogenomics J. 2003;3(4):242–7.

    Article  CAS  PubMed  Google Scholar 

  16. Mill J, Asherson P, Browes C, D’Souza U, Craig I. Expression of the dopamine transporter gene is regulated by the 3′ UTR VNTR: evidence from brain and lymphocytes using quantitative RT-PCR. Am J Med Gen. 2002;114(8):975–9.

    Article  Google Scholar 

  17. Hall FS, Itokawa K, Schmitt A, Moessner R, Sora I, Lesch KP, et al. Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems. Neuropharmacology. 2014;76(Pt A):146–55.

    Article  CAS  PubMed  Google Scholar 

  18. Colloby SJ, McParland S, O’Brien JT, Attems J. Neuropathological correlates of dopaminergic imaging in Alzheimer’s disease and Lewy body dementias. Brain Journal Neurol. 2012;135(Pt 9):2798–808.

    Article  Google Scholar 

  19. Kaasinen V, Joutsa J, Noponen T, Johansson J, Seppanen M. Effects of aging and gender on striatal and extrastriatal [123I]FP-CIT binding in Parkinson’s disease. Neurobiol Aging. 2015;36(4):1757–63.

    Article  CAS  PubMed  Google Scholar 

  20. Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain Journal Neurol. 1991;114(Pt 5):2283–301.

    Article  Google Scholar 

  21. Rivest R, Falardeau P, Di Paolo T. Brain dopamine transporter: gender differences and effect of chronic haloperidol. Brain Res. 1995;692(1–2):269–72.

    Article  CAS  PubMed  Google Scholar 

  22. Tripanichkul W, Jaroensuppaperch EO, Finkelstein DI. Estrogen enhances the number of nigral dopaminergic neurons of adult male mice without affecting nigral neuroglial number and morphology. Neurosci Lett. 2008;435(3):210–4.

    Article  CAS  PubMed  Google Scholar 

  23. Yoest KE, Cummings JA, Becker JB. Estradiol, dopamine and motivation. Cent Nerv Syst Agents Med Chem. 2014;14(2):83–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Moisan F, Kab S, Mohamed F, Canonico M, Le Guern M, Quintin C, et al. Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis. J Neurol Neurosurg Psychiatry. 2016;87(9):952–7.

    Article  PubMed  Google Scholar 

  25. Dickson JC, Tossici-Bolt L, Sera T, Erlandsson K, Varrone A, Tatsch K, et al. The impact of reconstruction method on the quantification of DaTSCAN images. Eur J Nucl Med Mol Imaging. 2010;37(1):23–35.

    Article  PubMed  Google Scholar 

  26. Kameiyama H, Matsutomo N, Nagaki A, Yamao F. Effect of reconstruction strategies for the quantification and diagnostic accuracy of (123)I-FP-CIT SPECT. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2016;72(7):595–601.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Dr. Yumiko Motoi is an Endowed Associate Professor of Department of Diagnosis, Prevention and Treatment of Dementia that has been sponsored by Nippon Medi-Physics Co. Ltd. She has received research grants from the company. Dr.Koji Murakami and Dr. Nobutaka Hattori have received a speaker honorarium from Nippon Medi-Physics Co. Ltd. Dr. shigeki Aoki has received research grants and a speaker honorarium from Nippon Medi-Physics Co. Ltd.

Author information

Authors and Affiliations

  1. Department of Radiology, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan

    Hideo Yamamoto, Shinichi Arimura, Atsushi Nakanishi, Koji Murakami & Shigeki Aoki

  2. Diagnosis, Prevention and Treatment of Dementia, Juntendo University Graduate of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan

    Yumiko Motoi & Nobutaka Hattori

  3. Department of Neurology, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan

    Yasushi Shimo, Yumiko Motoi, Koichi Ishiguro & Nobutaka Hattori

Authors
  1. Hideo Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shinichi Arimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Atsushi Nakanishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasushi Shimo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yumiko Motoi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Koichi Ishiguro
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Koji Murakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nobutaka Hattori
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shigeki Aoki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yumiko Motoi.

Ethics declarations

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Conflict of interest

This research was supported by Nihon Medi-Physics CO., Ltd.

Electronic supplementary material

Below is the link to the electronic supplementary material.

12149_2017_1168_MOESM1_ESM.tiff

Supplementary Fig. 1 95% family-wise confidence level of the differences in the SBR. The bars indicate the lower limits and upper limits of confidence intervals. If the bar does not include 0, the difference is regarded to be significant. A two-way ANOVA followed by Turkey’s HSD test was performed (TIFF 766 KB)

Supplementary Fig. 2 Relationship between SBR and smoking status (TIFF 898 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yamamoto, H., Arimura, S., Nakanishi, A. et al. Age-related effects and gender differences in Japanese healthy controls for [123I] FP-CIT SPECT. Ann Nucl Med 31, 407–412 (2017). https://doi.org/10.1007/s12149-017-1168-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-017-1168-1

Keywords

Search

Navigation